clinical trial · NCT06375733
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Large B-cell LymphomaGFH009ZanubrutinibGFH009Zanubrutinib
brief summary
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the safety and efficacy of GFH009 in combination with Zanubrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
started
Mar 20, 2024
primary completion
Dec 31, 2026
completion
Dec 31, 2026
last updated
Aug 12, 2025
official title
A Phase Ib/II, Multicenter, Open-label, Single-arm Study to Assess the Safety and Efficacy of GFH009 in Combination With Zanubrutinib in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol